Overview

Single Dose Lipopolysaccharide (LPS) Study In Healthy Volunteers

Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
A single dose study with the inhaled anti-inflammatory agent PF-03715455 to establish if it has anti-inflammatory activity following a challenge with LPS. Inhaled LPS invokes an acute inflammatory response in the lung which can be seen in induced sputum. PH-0797804 is an internal control for the study.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer